Novo Nordisk reports 'very encouraging' results for the FRONTIER2 phase 3 trial in 254 adults and adolescents aged 12 and over with inhibitor-positive and inhibitor-free hemophilia A, at the ISTH annual congress in Bangkok, Thailand.

According to the Danish pharmaceutical company, no bleeding was observed in 85.7% of people treated with its experimental product Mim8 once a week, and in 95% of those treated with Mim8 once a month.

Novo Nordisk aims to submit Mim8 for first regulatory approval towards the end of 2024. Data from the ongoing phase 3 FRONTIER program will be unveiled at upcoming congresses and in publications in 2024 and 2025.

Copyright (c) 2024 CercleFinance.com. All rights reserved.